GH Research (GHRS)
Develops mebufotenin therapies and delivery systems for treatment-resistant depression.
Something off on this page? Send us feedback.
Develops GH001, an inhaled mebufotenin candidate for treatment-resistant depression, and GH002, an intravenous candidate. The clinical-stage company depends on development, approvals, delivery devices, and external manufacturing.
Develops mebufotenin-based candidates aimed at depression. GH001 uses a proprietary inhalation delivery system and completed a Phase 2b trial in treatment-resistant depression; the company has said it is seeking FDA alignment for a global Phase 3 program based on that design. GH002 is its intravenous candidate, and its Phase 1 healthy-volunteer trial is complete.
GH001 and GH002 form the current portfolio, alongside development of associated delivery devices and manufacturing capabilities. Operations include clinical development in expanded geographies. Progress depends on clinical development, regulatory approvals, medical devices required for delivery, and external manufacturing capabilities.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | New Street | Target | Target: — | Target: $65 |
| Aug 7, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: $35 | Target: $40 |
| Aug 7, 2026 | Guggenheim | Reiterate | Rating: —Target: $34 | Target: $40 |
| Aug 6, 2026 | Needham | Reiterate | Rating: —Target: $32 | Target: $39 |
| Jul 27, 2026 | Wells Fargo | Initiate | Rating: —Target: — | Target: $44 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $362.7M · Total debt $360.0K · Total assets $372.3M · Shareholders' equity $359.5M
- Revenue
- $0
- Operating income
- −$19.5M
- Net income
- −$15.1M
No dividends on record.
| Institutions | 75.13% | 51.51M ADS | |
|---|---|---|---|
| 68 holders · as of Jun 30, 2026 | |||
| Other | 24.87% | 17.05M ADS | |
| remainder | |||
68.56M ADS as of Sep 2, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
LYNX1 Capital Management LPInstitution | 19.35% | 13.26M ADS | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 12.62% | 8.65M ADS | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 11.14% | 7.64M ADS | as of Jun 30, 2026 |
FMR LLCInstitution | 8.72% | 5.98M ADS | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 8.66% | 5.93M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Compass Pathways (ADR)
Phase 3 psilocybin program for treatment-resistant depression
- Johnson & Johnson
Approved esketamine nasal spray for treatment-resistant depression
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GH Research | $27.86 | −0.18% | $1.91B | — | — | — | — |
| Compass Pathways (ADR) | $14.85 | +0.51% | $2.03B | — | — | — | — |
| Johnson & Johnson | $269.17 | −0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Median | 31.2 | 22.7 | 6.6 | +6.6% |